Interesting and provokative article on developing #RadOnc as distinct medical speciality in the UK, by @alison_tree @SullivanProf @AggarwalOnc et al. Suggests: ➡️Exclusive reliance on dual-trained oncologists limits radiation oncology recruitment ➡️Rad Onc role-specific pathway could expand radiotherapy workforce capacity What do others think: @cpeedell @gwalls89 @finn_corinne ? Should the @RCRadiologists start to scope this out? 🔗sciencedirect.com/science/ar…

Now out in #JCO! 👇 ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide with Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer. Read the article. bit.ly/4zRcWMR #ProstateCancer #pcsm

Fantastic paper led by from @APCCC_Lugano group about high-risk localized prostate cancer management in @EUplatinum kwnsfk27.r.eu-west-1.awstrac…

🚨📣📣 #ESMO26 presidential: @niazi_Dr7 Adding darolutamide to ADT + RT dramatically ⬇️ risk of metastasis or death in high-risk localized prostate cancer. Phase 3 DASL-HiCaP = 58% ⬇️ in MFS (HR 0.42) + early OS signal (HR 0.88). #ProstateCancer #RadOnc #pcsm @ChrisSweens1

#ESMO26 PROTEUS discussion by Nicholas van As • No baseline PSMA PET; enrolled conventionally staged M0 • MFS events: true progression or delayed detection? Most were PSMA PET-detected (8.8% vs 16.3%) • TTST HR 0.29, but ~20-mo lead-time bias #ProstateCancer

Interesting for sure!🙂 When we look at MFS, the composite one including PSMA-PET, we can see that events start increasing at around the median time for T recovery (~20 months) in the APA/ADT arm, then the curve starts looking very similar to the red one. Looks to me more like a time-shift in detecting these mets due to T-suppression (dashed blue line is the blue curve shifted by 21 months), as imaging was initiated at biochemical failure. @jryckman3 @5_utr @adib_elio @Soum_Roy_RadOnc @DrSpratticus @ChapinMD @brookmans76 @PCaParker @alison_tree @cpeedell @seanmmcbride

Worth reading: a sharp analysis of PROTEUS trial results by @DrSpratticus 👇 nature.com/articles/s41571-0…

Our #ZZFIRST trial is out today in @NatureMedicine! An academic randomized phase II trial of Talazoparib + Enzalutamide in high-volume mHNPC integrating spatial transcriptomics on longitudinal tumor biopsies. Thanks to all patients and funding from DoD/CDMRP + @ContraCancerEs

ARIEL trial: 📄 and🧵on MRI🧲 changes with RT+ADT for #ProstateCancer 👇🏼 @OncoAlert @UroToday @imagingprostate @ASTRO_org @PCF_science @MedwatchHQ #practicalRO #ASTRO26 @adornisch_MD @DrRanaMcKay @medmund14 @UCSDRadMed @DrTylerStewart @UCSDCancer

8️⃣ end 🙏🏼Patients who got in the 🧲 tube for research 🙏🏼Physicians who enrolled patients 🙏🏼Research team for consenting and collecting data 🙏🏼@ASTRO_org @PCF_Science for funding the trial

An essay worth reading, for every clinician and patient (with a PrCa paragraph) The Quiet Half of Good Medicine jamanetwork.com/journals/jam…

A day in the life of a @NHSEngland palliative medicine consultant @JoeHawk75825077 blogs.bmj.com/spcare/2026/01…

As someone who regards themselves as a socially progressive, pro-human rights, liberal, atheist, NHS palliative care doctor, I want to challenge your framing of AD as “socially progressive”, Luke. Freedom to choose state assistance in ending your life has to be balanced against ensuring vulnerable people are not coerced into ending their lives prematurely by AD - whether this is due to subtle societal messages that your life has no value, or lack of the basic palliative & social care that might make your life still worth living, or pressure from self-interested individuals. How is protecting the vulnerable the opposite of “socially progressive”? How is the elevation of personal freedom above other values synonymous with “socially progressive”? There’s a reason so many medical bodies & those representing disabled people opposed this bill - and it’s not social conservatism, it’s concern for vulnerable people. (I see more death & dying than almost anyone & I happen to be pro AD, btw, provided a legal change is safe. This bill was very far from that.)

PFS endpt treats different events as equivalent, but how well do oligomet RT trials tell us what us what actually constituted progression? In this study led by Cole Friedes, we found across 21 RCTs, event-level reporting was limited...🧵1/2 @OncoAlert thegreenjournal.com/article/…

…only 24% specified the 1st PFS event, & clinically relevant consequences were rarely reported. Rather than abandoning PFS, we propose a simple 5-item reporting rubric to deconstruct it into clinically meaningful events. Take a read & congrats to Cole! 2/2

⚠️ 🌍 ⚠️ We stand with humanity: A scientist statement to confront climate destruction⚠️ 🌍 ⚠️ ✒️ 🙏 If you are an academic or healthcare professional, please consider signing. 🙏✒️ framaforms.org/we-stand-with…

Congratulations to the investigators and a huge thank you to the participants! My brief take on GETUG-18 in @TheLancetOncol 👇🏼 ✅ higher RT dose ➡️ recurrence📉 🎉 ❌ OS benefit driven by non-PCa events 💪🏼 focal RT boost 🟰sweet spot 🔥 @OncoAlert @urotoday @APCCC_Lugano

Very nice editorial by @TylerSbrt Radiotherapy dose intensification for high-risk prostate cancer—what is gained? - The Lancet Oncology thelancet.com/journals/lanon…

GETUG-AFU 18 @TheLancetOncol @HennequinChris6 thelancet.com/journals/lanon…